Literature DB >> 17566017

The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer.

Imke Atreya1, Carl C Schimanski, Christoph Becker, Stefan Wirtz, Heike Dornhoff, Elke Schnürer, Martin R Berger, Peter R Galle, Wolfgang Herr, Markus F Neurath.   

Abstract

BACKGROUND/AIMS: An efficient cytolytic T cell function is essential for immune mediated rejection of colorectal cancer. However, the molecular mechanisms driving T cell mediated cancer rejection are still poorly understood. Here, we assessed the relevance of the T-box transcription factor eomesodermin in colorectal cancer. METHODS/
RESULTS: By analysing tissue probes from 88 different colorectal tumours, a significant (p<0.02) inverse correlation between eomesodermin expression in colorectal cancers and the presence of lymph node metastases could be shown, whereas no such correlation was noted for the master transcription factor of regulatory T cells, FoxP3 and CD8 alpha expression. To evaluate whether this effect might be due to effects of eomesodermin on tumour infiltrating CD8 T cells, we subsequently analysed the regulated expression and function of this transcription factor in human T cells. Whereas overexpression of this factor induced perforin but not granzyme expression, siRNA mediated suppression of eomesodermin expression led to significantly reduced IFN-gamma production, perforin levels and cytolytic activity of CD8 T cells. Furthermore, TGF-beta and IL4 could be identified as important inducer of eomesodermin expression.
CONCLUSION: These data define for the first time a regulatory role of eomesodermin for CD8 T cell activity in humans. Our findings are consistent with a model in which eomesodermin expression in tumour infiltrating T cells regulates cytolytic functions of CD8 T cells via perforin expression. These data provide novel insights into control mechanisms governing the functional activity of human CD8 T lymphocytes via T-box transcription factors in cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17566017      PMCID: PMC2095672          DOI: 10.1136/gut.2006.117812

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.

Authors:  L Gorelik; P E Fields; R A Flavell
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

3.  TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes.

Authors:  J J Bright; L D Kerr; S Sriram
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

Review 4.  Colon cancer and the immune system: the role of tumor invading T cells.

Authors:  Maximilian Waldner; Carl-C Schimanski; Markus-F Neurath
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

5.  Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells.

Authors:  Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

6.  Eomesodermin, a key early gene in Xenopus mesoderm differentiation.

Authors:  K Ryan; N Garrett; A Mitchell; J B Gurdon
Journal:  Cell       Date:  1996-12-13       Impact factor: 41.582

Review 7.  TGF-beta signaling in tumor suppression and cancer progression.

Authors:  R Derynck; R J Akhurst; A Balmain
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

8.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

Review 9.  The role of CD8(+) T cells in immune responses to colorectal cancer.

Authors:  Liviu V Titu; John R T Monson; John Greenman
Journal:  Cancer Immunol Immunother       Date:  2002-04-20       Impact factor: 6.968

10.  CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.

Authors:  Andreas Dörrschuck; Andrea Schmidt; Elke Schnürer; Matthias Glückmann; Christian Albrecht; Catherine Wölfel; Volker Lennerz; Alexander Lifke; Carmela Di Natale; Elena Ranieri; Loreto Gesualdo; Christoph Huber; Michael Karas; Thomas Wölfel; Wolfgang Herr
Journal:  Blood       Date:  2004-07-01       Impact factor: 22.113

View more
  22 in total

1.  Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI.

Authors:  Vanessa Deschoolmeester; Marc Baay; Filip Lardon; Patrick Pauwels; Marc Peeters
Journal:  Cancer Microenviron       Date:  2011-05-27

2.  Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.

Authors:  Jooeun Bae; Mehmet Samur; Aditya Munshi; Teru Hideshima; Derin Keskin; Alec Kimmelman; Ann-Hwee Lee; Glen Dranoff; Kenneth C Anderson; Nikhil C Munshi
Journal:  Oncoimmunology       Date:  2014-12-02       Impact factor: 8.110

Review 3.  Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Authors:  Fabio Grizzi; Gianluca Basso; Elena Monica Borroni; Tommaso Cavalleri; Paolo Bianchi; Sanja Stifter; Maurizio Chiriva-Internati; Alberto Malesci; Luigi Laghi
Journal:  Inflamm Res       Date:  2018-01-10       Impact factor: 4.575

Review 4.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

5.  Increased peripheral IL-4 leads to an expanded virtual memory CD8+ population.

Authors:  Vanessa Kurzweil; Ami LaRoche; Paula M Oliver
Journal:  J Immunol       Date:  2014-05-02       Impact factor: 5.422

6.  Reciprocal regulation of BMF and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer.

Authors:  Rong Wang; Yuki Kang; Christiane V Löhr; Kay A Fischer; C Samuel Bradford; Gavin Johnson; Wan Mohaiza Dashwood; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Cancer Lett       Date:  2016-08-15       Impact factor: 8.679

Review 7.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

Review 8.  Colitis-associated cancer: the role of T cells in tumor development.

Authors:  Maximilian J Waldner; Markus F Neurath
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

9.  Gadd45b and Gadd45g are important for anti-tumor immune responses.

Authors:  Songguang Ju; Yibei Zhu; Lin Liu; Shao Dai; Changyou Li; Elizabeth Chen; Yukai He; Xueguang Zhang; Binfeng Lu
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

10.  Technical Advance: Fluorescent reporter reveals insights into eomesodermin biology in cytotoxic lymphocytes.

Authors:  Michael A Paley; Scott M Gordon; Elizabeth K Bikoff; Elizabeth J Robertson; E John Wherry; Steven L Reiner
Journal:  J Leukoc Biol       Date:  2012-11-27       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.